A Comparison Study for Chances of Reduction in Cardiovascular Risk by Draksharishta in Induced Diabetic Condition

Volume 1 - Issue 3

Subhajit Ghosh¹*, Dr PN Murthy² and Dr H Joshi¹

Received: April 14, 2018;   Published: April 19, 2018

DOI: 10.32474/DDIPIJ.2018.01.000111

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

In this study was to evaluate the effect of Draksharishta-T and Draksharishta -M prepared by traditional and modern methods respectively and Dabur Draksharishta and comparison between them on fasting blood glucose and serum lipid profile in alloxan induced diabetic rats. Oral administration of Draksharishta-T, Draksharishta-M and Dabur Draksharishta (2ml/kg p.o.) for 21 days caused a significant decrease in fasting blood glucose (FBG) and showed significant rise in blood glutathione level (GSH) in diabetic rats. Glibenclamide was used as a standard anti diabetic drug (10 mg/kg, p.o). These preparations also caused significant reduction in serum cholesterol, LDL and triglycerides and showed significant rise in serum HDL level in diabetic albino rats. Thus all these preparations were able to maintain the tested parameters near to the normal level significantly.

Keywords: Draksharishta; Blood glucose; Anti-diabetic; Cardiovascular risk; Glutathione; Lipid profile; Alloxan

Abbrevations: FBG: Fasting Blood Glucose; GSH: Blood Glutathione Level; WHO: World Health Organization; CPCSEA: Committee for the Purpose of Control and Supervision of Experiments on Animals; ANOVA: Analysis of Variance

Abstract| Introductiom| Materials and Methods| Results| Discussion| Acknowledgement| Refernces|